Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Xijing Hospital
AbbVie
Laekna Limited
Hoffmann-La Roche
Merck Sharp & Dohme LLC
AstraZeneca
Celgene